ViCentra Raises $13M in Series D extension Funding

The additional capital supports European manufacturing and sales expansion and preparations for US market access.

Round size
$13M
Stage
Series D extension
Headquarters
Netherlands
Announced
Jan 8, 2026

Wearable insulin delivery

Kaleido is a compact patch-pump system designed to give users flexibility in how they wear and manage their insulin pump. ViCentra manufactures and commercializes the device from its base in Utrecht.

Scaling supply and preparing the next market

The company will scale manufacturing and strengthen commercial operations in Germany, the Netherlands and France. It is also preparing its next-generation system for US access. This closing adds $13 million to the $85 million raised in September 2025, bringing the Series D total to $98 million.

Sources

  1. ViCentra: funding announcement
  2. Drug Delivery Business: ViCentra second closing
03 / Related rounds

Related funding rounds

01
Series C+ · AI

xAI

Grok AI models for conversation, coding, voice and image generation.

$20B
02
Series C+ · Robotics

Skild AI

Skild AI develops a shared robotics foundation model that controls different robot bodies, including mobile manipulators, tabletop arms, quadrupeds and humanoids.

Led by SoftBank
$1.4B
03
Series C+ · Autonomous Vehicles

Waabi

Waabi develops autonomous-driving software for trucks and robotaxis, using a shared AI model and simulation to train and validate driving behavior.

Led by Khosla Ventures, G2 Venture Partners
$750M